AFT Pharmaceuticals (ASX:AFP, NZE:AFT) reported Thursday that its earnings per diluted share in fiscal 2025 fell to NZ$0.11 from NZ$0.15 a year earlier.
Revenue for the year ended March 31 was NZ$208 million, up from NZ$195.4 million in the same period a year earlier.
The company expects fiscal 2026 operating profit in the range of NZ$20 million to NZ$24 million.
The board declared a final dividend of NZ$0.018 per share, up from NZ$0.016 a year earlier, payable on July 4 to shareholders on record as of June 20.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.